

Changes in allergenicity of ovalbumin in vitro and vivo on conjugation with quercetin

Tingting Zhang, Zongyi Hu, Yongwei Cheng, Haoxie Xu, Tanja Cirkovic Velickovic, Kan He, Fan Sun, Zhendan He, Zhigang Liu, and Xuli Wu

J. Agric. Food Chem., **Just Accepted Manuscript** • DOI: 10.1021/acs.jafc.0c00461 • Publication Date (Web): 17 Mar 2020

Downloaded from pubs.acs.org on March 18, 2020

Just Accepted

“Just Accepted” manuscripts have been peer-reviewed and accepted for publication. They are posted online prior to technical editing, formatting for publication and author proofing. The American Chemical Society provides “Just Accepted” as a service to the research community to expedite the dissemination of scientific material as soon as possible after acceptance. “Just Accepted” manuscripts appear in full in PDF format accompanied by an HTML abstract. “Just Accepted” manuscripts have been fully peer reviewed, but should not be considered the official version of record. They are citable by the Digital Object Identifier (DOI®). “Just Accepted” is an optional service offered to authors. Therefore, the “Just Accepted” Web site may not include all articles that will be published in the journal. After a manuscript is technically edited and formatted, it will be removed from the “Just Accepted” Web site and published as an ASAP article. Note that technical editing may introduce minor changes to the manuscript text and/or graphics which could affect content, and all legal disclaimers and ethical guidelines that apply to the journal pertain. ACS cannot be held responsible for errors or consequences arising from the use of information contained in these “Just Accepted” manuscripts.

Changes in allergenicity of ovalbumin *in vitro* and *vivo* on conjugation with quercetin

Tingting Zhang ^a, Zongyi Hu ^{a,b}, Yongwei Cheng ^{a, c}, Haoxie Xu ^a, Tanja Cirkovic Velickovic ^{d, f}, Kan He ^a, Fan Sun ^a, Zhendan He ^a, Zhigang Liu ^a, Xuli Wu ^{a*}

^a School of Public Health, Health Science Center, Shenzhen University, Shenzhen, Guangdong Province, PR China, 518060

^b Department of Anesthesiology, Shenzhen Nanshan Maternity and Child healthcare Hospital, Shenzhen, Guangdong Province, PR China, 518060

^c Department of Obstetricians and Gynaecologists, Shenzhen University General Hospital, Shenzhen, Guangdong Province, PR China, 518060

^d Center of Excellence for Molecular Food Sciences & Department of Biochemistry, University of Belgrade-Faculty of Chemistry, Belgrade, Serbia

^fGhent University Global Campus, Incheon, South Korea

* Corresponding author:

School of Public Health, Health Science Center, Shenzhen University

Nanhai Ave 3688, Shenzhen, Guangdong, P.R. China 518060

Tel: +86 755 86671909; Fax: +86 755 86671906;

E-mail addresses: wxl@szu.edu.cn

Tingting Zhang and Zongyi Hu contributed equally to this work.

1 ABSTRACT

2 Previous study demonstrated decreased allergenicity *in vitro* of some food
3 allergens after conjugation with polyphenols. However, little is known about how
4 polyphenol conjugation with food allergens affects *in vivo* allergenicity. We
5 conjugated a well-known food allergen, ovalbumin (OVA), with quercetin (QUE) to
6 assess the potential allergenicity of OVA *in vitro* and *in vivo* in a BALB/c mouse
7 model. QUE could covalently conjugate with OVA and changed the protein structure,
8 which might destroy and/or mask OVA epitopes. Conjugation with QUE decreased
9 IgE-binding properties and the release capacity of the conjugated OVA. *In vivo*, as
10 compared with native protein, conjugation with QUE decreased the levels of IgE,
11 IgG1, IgG, plasma histamine and mast cell protease-1 (mMCP-1) on the surface of
12 sensitized mast cells, along with decreased FcεRI⁺ and c-kit⁺ expression. The levels of
13 Th2-related cytokines (IL-4, IL-5, IL-13) decreased and that of a Th1-related cytokine
14 (IFN-γ) increased slightly, which suggests that conjugation with QUE modulated the
15 imbalance of the Th1/Th2 immune response. Conjugation of OVA with QUE could
16 reduce OVA allergenicity *in vitro* and *in vivo*, which could provide information for
17 reducing food allergenicity by conjugation with polyphenols.

18

19 **KEYWORDS:** OVA, Quercetin, Conjugation, Allergenicity, Mouse model

20 INTRODUCTION

21 Food allergy is an important public health issue and affects about 8% of children
22 and 5% of adults, with increasing incidence in the past few years ¹. Egg allergy is one
23 of the most common food allergies, particularly in children under the age of 3 ².

24 Ovalbumin (OVA, 45 kDa) is one of the major allergens in egg causing
25 IgE-mediated allergic reactions, the most frequent. Processing techniques for
26 destroying the allergenicity of OVA in egg white have wide interest ³. Among the
27 potential alteration methods, the interaction between polyphenols and allergens can
28 reduce allergenicity by changing the protein structure or rendering the allergen less
29 bioavailable ⁴.

30 Polyphenols can bind protein by non-covalent and covalent interaction ^{5,6}. A
31 number of studies have investigated the interaction between polyphenols and food
32 allergens. Polyphenol interactions can reduce the immunogenicity and allergenicity of
33 wheat gliadins ⁷. Caffeic, chlorogenic acids and ferulic can bind to Ara h1 and Ara h2,
34 which reduces the IgE binding of the protein ⁸. The IgE-binding capacity of the major
35 cherry allergen Pru av 1 was reduced after interaction with gallic acid, quercetin and
36 epicatechin ⁹. Previous studies have found reduced IgE-binding and degranulation
37 capacities of peanut flour after interaction with polyphenolic extracts rich in
38 pro-anthocyanidins and anthocyanins ¹⁰⁻¹². Furthermore, an *in vivo* study
39 demonstrated that complexation of polyphenols to peanut flour inhibited specific IgE
40 antibody production in peanut-sensitized mice ¹³. Our previous report of the reduced
41 IgE- and IgG-binding activities of β -lactoglobulin after catechin binding supports the

42 above findings¹⁴. Considering these findings, interaction with polyphenols might be a
43 potential novel strategy for producing hypoallergenic food.

44 Non-covalent binding of epigallo-catechin 3-gallate (EGCG) to OVA resulted in
45 structural changes in protein. However, EGCG did not prevent the IgE–OVA
46 interaction¹⁵. As compared with covalent interactions between polyphenols and
47 proteins, non-covalent interactions are reversible, with lower affinity¹⁶, which
48 suggests that reducing the allergenicity of food allergen by non-covalent interactions
49 is limited in food processing. We have investigated the effect of covalent interactions
50 with polyphenols on the allergenic capacity of OVA. After conjugation with
51 polyphenols, the IgE-binding of OVA decreased, with increased emulsifying and
52 foaming properties, antioxidant activity and digestibility¹⁷⁻¹⁸. However, whether
53 covalent conjugation with polyphenols can reduce the allergenic properties of OVA
54 needs to be confirmed by *in vivo* studies.

55 Quercetin (QUE) is a common dietary polyphenol in many plant foods. In this
56 study, we prepared OVA–polyphene conjugates by covalent interaction with QUE
57 and investigated the covalent interaction and structural changes. The changes in
58 allergenicity of OVA *in vitro* were evaluated by IgE-binding capacity and human
59 basophil leukemia (KU812) cell degranulation assay. Furthermore, we used a mouse
60 model of orally induced OVA allergy to evaluate the allergenicity of OVA after
61 conjugation with QUE *in vivo*, which could provide pre-clinical data for the
62 development of innovative hypoallergenic food products.

63

64 **MATERIALS AND METHODS**

65 **Materials**

66 OVA (protein content >98 %), QUE (purity \geq 95%),
67 1,10-diphenyl-2-picrylhydrazyl (DPPH), Folin-Ciocalteu phenol reagent,
68 3,3'-5,5'-tetramethylbenzidine (TMB) and
69 2,2-azinobis(3-ethylbenzthiazoline)-6-sulfonic acid (ABTS) were from Sigma-Aldrich
70 (St. Louis, MO, USA). Mouse IgG-antihuman IgE antibody and
71 NeutrAvidin-HRP-conjugated antibody were from SouthernBiotech (Birmingham,
72 AL, USA). Horseradish peroxidase (HRP)-conjugated goat anti-human IgE was from
73 Kirkegaard & Perry Laboratories (Gaithersburg, MD, USA).

74 Serum samples from 12 children who were allergic to OVA were generously
75 provided by Shenzhen Children's Hospital (Guangdong, China), and the availability
76 was approved by the human ethics committee of Health Science Center at Shenzhen
77 University (Permit No. 201606016). Each individual signed an informed consent. All
78 anti-OVA-specific IgE levels in serum samples were > 10 kU/L. Pooled normal
79 serum samples from individuals (n=5) without allergy to chicken egg were negative
80 controls.

81

82 **Preparation of samples**

83 The OVA-QUE conjugates were prepared by the alkaline method or free radical
84 method. To prepare conjugates by the alkaline method as described previously¹³, 0.25
85 g OVA was dissolved in 50 mL distilled H₂O and the pH was adjusted to 9.0, then

86 samples were maintained at 25 °C for 2 h under atmospheric air. A 0.5-mmol amount
87 of QUE was added to the mixture with continuous stirring for 24 h. The unreacted
88 QUE was removed by dialysis at 4 °C for 48 h with Milli-Q water. The free radical
89 method was performed as described ¹⁹ with modification. After dissolving 0.5 g OVA
90 in 50 mL distilled H₂O, 1.0 mL 5.0 M H₂O₂ and 0.25 g ascorbic acid were added to
91 the solution, then samples were maintained at 25 °C. After 2 h, 0.35 mmol QUE was
92 added to the solution and maintained at 25 °C for 24 h. Unreacted QUE was removed
93 as described above. Finally, the conjugates were obtained by freezing and drying
94 samples.

95 The contents of conjugates were detected by the Foline-Ciocalteu method as we
96 previously described ²⁰, with QUE as a standard. Determining free amino groups in
97 samples involved use of trinitro-benzene-sulfonic acid as previously described ²¹. The
98 contents of sulfhydryl thiol groups and tyrosine in samples were measured as we
99 previously described ¹⁹.

100

101 **SDS-PAGE**

102 SDS-PAGE was performed on a 5% stacking gel and 12% separating gel. A
103 10- μ L loading buffer (Solarbio Life Science, Beijing) was mixed with 40 μ L samples (1
104 mg/mL) and heated at 95 °C for 5 min. Then aliquots were loaded on the gels. After
105 staining with Coomassie Brilliant Blue R-250 for 0.5 h, gels were destained with
106 7.5% acetic acid and 5% methanol for 10 h and scanned.

107

108 **Structural analysis of conjugates**

109 *Fourier transform infrared (FTIR) spectroscopy*

110 The FTIR spectra were detected as previously described ²² by using a
111 FTIR-8300PCS spectrometer (SHIMADZU Co., Kyoto, Japan) with KBr pellets. The
112 samples were measured at 25 °C in the range of 400 to 4000 cm⁻¹ with 32 scans and
113 4 cm⁻¹ resolution.

114

115 *Circular dichroism (CD)*

116 CD was performed as previously described ²³. The ellipticity of samples (0.015
117 mg/mL) was recorded on a Jasco-810 spectrophotometer (Jasco Co., Japan) with
118 resolution 0.2 nm and 100 nm/min speed step in the range of 190-250 nm at 25 °C.

119

120 *Differential scanning calorimetry (DSC)*

121 DSC was used to examine the thermal stability of samples by using a DSC-60
122 calorimeter (Shimadzu, Tokyo). A 5-mg sample was placed in an aluminum pan that
123 was sealed tightly. Using nitrogen as the transfer gas at a rate of 30 mL/min, the
124 thermal analyses were performed from 30 to 180 °C with a constant rate of 5 °C/min.

125

126 **In vitro allergenicity assessment**

127 Competitive inhibition of ELISA was used to measure the IgE-binding ability of
128 samples. A 100 µL sample solution (2 mg/ml) was added to a 96-well microplate and
129 incubated overnight at 4 °C. After a wash with phosphate buffered saline (PBS)

130 containing 0.05% Tween-20 (PBST), plates were blocked with 2% fish gelatin in
131 PBST for 1 h at 37°C, then washed with PBST. A 50- μ L amount of serum pool from
132 egg-allergic patients (diluted 1:200) was mixed with 50 μ L of sample solution and
133 added to each well. After incubation for 1 h, plates were washed. A 100- μ L amount of
134 HRP-conjugated goat anti-human IgE antibody (1:10,000) was added to wells and
135 incubated for 40 min at 37 °C. After a wash, 50 μ L substrate was added. The reaction
136 was stopped by adding 50 μ L H₂SO₄ (2 M), and absorbance at 450 nm was measured.

137

138 **Antioxidant activity analysis of OVA–QUE conjugate**

139 *DPPH scavenging activity*

140 DPPH scavenging activity of OVA and OVA–QUE conjugates was measured as
141 previously described²⁰. In brief, 2 mL DPPH was mixed with 2 mL sample (0.5
142 mg/mL). The mixture was stored in the dark for 1 h. Finally, the absorbance at 517
143 nm was measured.

144

145 *ABTS+ scavenging activity*

146 ABTS+ scavenging activity of OVA and OVA–CHA conjugates was performed
147 as previously described²⁰. In brief, 3 mL ABTS reagent was mixed with 1 ml sample
148 (0.5 mg/mL). The mixture was incubated for 1 h at 25 °C. Finally, the absorbance at
149 734 nm was measured.

150

151 *Cell model analysis*

152 The immature prebasophilic cell line (KU812) was purchased from the Chinese
153 Academy of Sciences (Shanghai). Cells were cultured and the contents of histamine
154 and IL-6 in cells were measured as described²⁴ with little modification. The cells
155 were maintained in IMDM (Gibco, Shanghai) supplemented with 1%
156 penicillinstreptomycin (100x stock; GibcoBRL, Grand Island, NY) and 5% fetal
157 bovine serum (FBS, Gibco, Australia) and cultured in a humidified atmosphere with
158 5% CO₂ at 37 °C. KU812 cells (1×10⁷ cells/mL) were pre-incubated with 100 μL
159 serum from egg-allergic patients (v/v=5:1). Normal serum was a negative control.
160 After incubation for 24 h, 10 μL protein sample (5 mg/ml) was added and incubated
161 for 4 h. After centrifugation, supernatant was collected to detect the contents of
162 histamine and IL-6 by using human histamine and human IL-6 ELISA kits
163 (Elabscience Biotech, Wuhan, China).

164

165 **Animal model analysis**

166 *Mice*

167 All female BALB/c mice (5-6 weeks) were approved by SPF (Beijing)
168 Biotechnology. Animal experiments were carried out according to protocols approved
169 by the Animal Care and Use Committee of Health Science Center of Shenzhen
170 University (Permit No. 201711003). We used 40 female BALB/c mice in this study.
171 Before experiments, mice were housed and fed an OVA-free dietary for least 1 week.
172 All mice were divided into four groups: control (healthy mice without stimulation),

173 OVA, and radical and alkaline OVA–QUE conjugate groups.

174

175 *Oral sensitization and challenge of mice*

176 Mice were sensitized orally with a lavage needle on days 0, 7, 14,21 and 28 with
177 5 mg native OVA dissolved in PBS, which was mixed with 15 µg cholera toxin
178 (Sigma–Aldrich, St. Louis, MO, USA) as an oral sensitization (Figure 4A). The mice
179 of the control group were sensitized with 15 µg cholera toxin dissolved in PBS, then
180 challenged with PBS (500 µl) alone on day 35. The other three mouse groups — OVA
181 and radical and alkaline OVA–QUE — were orally challenged on day 35 with 20 mg
182 OVA or radical or alkaline OVA–QUE conjugate in 500 µl PBS, respectively. After 1
183 h, a validated anaphylactic scoring (Table 1) was used to determine the allergic or
184 anaphylactic symptoms of mice. Then mice were euthanized and blood, peritoneal
185 fluid and spleens were collected for measuring the following biomarkers.

186

187 *Determination of allergen-specific immunoglobulins (Ig)*

188 IgE, IgG and IgG₁ were determined by ELISA. In brief, 100 µl of 6 mg/mL
189 ELISA coating buffer (pH 9.6) was added to 96-well plates and incubated overnight.
190 Serum from each mouse group (n =5/group) was pooled in equal volumes (100 µl)
191 before analyses. Each diluted serum sample (1:20 for specific IgE, 1:8000 for specific
192 IgG and IgG₁) was added to plates. HRP-labeled goat anti-mouse IgE, IgG and IgG₁
193 (1:2000) antibodies (BD Pharmingen, Mississauga, ON, Canada) were added to
194 determine the binding of IgE, IgG and IgG₁. Finally, o-phenylenediamine substrate

195 (Sigma–Aldrich, St. Louis, MO, USA) was added for color development.

196

197 *Detection of mouse mast cell protease-1 (mMCP-1) in serum*

198 Serum was collected from mice (n=5/group) after 1-h challenge. The content of
199 mMCP-1 in serum was analyzed by using an mMCP-1 ELISA kit (Elabscience
200 Biotech, Wuhan, China) in accordance with the manufacturer's instructions.

201

202 *Morphological structure of duodenum*

203 After 1-h challenge with OVA or radical and or OVA–QUE, 4 mice in each
204 group were euthanized. A 4-cm segment of the duodenum was removed from the
205 mice immediately, then fixed with 10% formalin, and processed by standard
206 histological techniques. Samples sectioned at 5- μ m thickness were stained with eosin
207 and hematoxylin. Finally, a light microscope (Nikon Ti Microscope, Japan) was used
208 to observe the morphological structure of the small intestine.

209

210 *Cytokine analysis*

211 Individual spleens were aseptically removed from mice (n=6/group). After gently
212 grinding spleens by using a syringe plunger, the contents were passed through a
213 100- μ m nylon membrane cell strainer. After erythrocyte lysis, spleen cells were
214 cultivated in complete medium (RPMI-1640 containing 2 mM/L-glutamine, 10% fetal
215 bovine serum, 25 mM HEPES buffer, 100 mg/mL streptomycin and 100 IU/mL
216 penicillin). Cells (2×10^6 /well) were cultured in 48-well plates for 72 h in the presence

217 of OVA or radical or alkaline OVE-QUE conjugate (50 $\mu\text{g}/\text{ml}$). The supernatant was
218 collected, then IL-4, IL-5, IL-13 and IFN- γ contents were measured by using ELISA
219 kits (Elabscience Biotech, Wuhan, China).

220

221 *Histamine levels in mouse plasma*

222 Plasma was collected from mouse blood (n=5/group) and centrifuged for 10 min
223 at 4000 g. Plasma histamine was measured by using a histamine ELISA kit
224 (Elabscience Biotech, Wuhan, China).

225

226 *Identification of peritoneal mast cells in mice*

227 After challenge, peritoneal mast cells were collected from mice (n=6/group). In
228 the initial step, 5 ml RPMI-1640 containing 10% fetal bovine serum was injected into
229 the mouse's peritoneal cavity. After the mouse's abdomen was massaged softly for 1
230 min, peritoneal fluid containing mast cells was collected. After centrifugation at 150 g
231 for 10 min, cells were suspended in flow cytometry staining buffer.

232 The expression of the IgE receptor (Fc ϵ RI) and c-kit was detected in mast cells.
233 After staining with APC-conjugated anti-mouse-Fc ϵ RI antibody (0.25 $\mu\text{g}/\text{test}$, clone
234 MAR-1, Biolegend, San Diego, CA) and PE-conjugated anti-c-kit antibody (0.06
235 $\mu\text{g}/\text{test}$, clone 2B8, Biolegend, San Diego, CA) for 30 min in the dark at 4 $^{\circ}\text{C}$, cells
236 were washed twice with flow cytometry staining buffer before flow cytometry.

237

238 **Statistical analysis**

239 All sample determinations were carried out in triplicate. All data are expressed as
240 mean \pm SD. Differences were determined by using ANOVA and the Duncan least
241 significant difference test. $P < 0.05$ was considered statistically significant.

242

243 **RESULTS AND DISCUSSION**

244 **Profile of the OVA–QUE conjugates**

245 The band of OVA was about 45 kD after conjugation with QUE (Figure 1A). As
246 compared with native OVA, the bands of radical and alkaline OVA–QUE conjugates
247 migrated up, which suggested that conjugation with QUE increased the molecular
248 weight of OVA. The polyphenol content of radical and alkaline OVA–QUE was
249 increased (Table 2), which suggests the conjugation of OVA with QUE.

250 The content of thiol groups was decreased in OVA with QUE conjugation (Table
251 2), which suggested that QUE covalently conjugated with some free amino groups in
252 OVA²⁰. The DPPH and ABTS⁺ values for OVA conjugates were 2 to 3 times higher
253 than that for unmodified protein, because of more hydroxyl groups in QUE introduced
254 on the protein.

255 The above results indicate the covalent interaction between QUE and OVA.

256

257 **Structural analysis of the OVA–QUE conjugates**

258 Information on changes in the structure of OVA before and after QUE
259 conjugation was obtained by using FTIR and CD spectroscopy and DSC. FTIR

260 spectra can help provide information about the changes in the protein secondary
261 structure. The FTIR spectra of samples are in Figure 2A. Protein amide I (1600–1700
262 cm^{-1}) and amide II ($\approx 1530 \text{ cm}^{-1}$) have a relationship with the secondary structure of
263 protein. As compared with native OVA, the peak positions of the amide I band for
264 radical and alkaline OVA–QUE conjugates moved from 1653.08 to 1657.05 and
265 1651.90, respectively, and peak positions of the amide II band moved from 1537.85 to
266 1534.83 and 1538.07, respectively. The results suggested that the secondary structure
267 of the OVA was changed after conjugation with QUE.

268 CD spectra were used to further analyze the changes in OVA secondary structure
269 after conjugation with QUE. Figure 2B shows that all spectra exhibited a negative
270 band (222 nm), which is characteristic of α -helical structures in protein. As compared
271 with native OVA, the absolute θ values of this negative band for the conjugates
272 decreased, which indicates loss of some α -helical structures in the conjugates¹⁹. A
273 similar result was obtained previously²⁵, with decreased α -helical structures of OVA
274 after conjugation with catechin.

275 The protein structure is related to the thermal stability of the protein. We used
276 DSC to study the thermal stability of the protein. Figure 2C shows that the thermal
277 denaturation temperatures of OVA and radical and alkaline OVA–QUE conjugates
278 were 98.4, 94.9 and 66.6 °C respectively, so the tertiary conformation stability of
279 OVA was decreased after covalent conjugation with QUE.

280 The structural analysis suggested that covalent conjugation with QUE changed
281 the protein secondary structure and caused the unfolded protein structure of OVA. In

282 a previous study, we also found that covalent conjugation with EGCG and
283 chlorogenic acid caused an unfolded OVA structure¹⁷⁻¹⁸.

284

285 **In vitro assessment of allergenicity**

286 The *in vitro* allergenic capacity of the native OVA and conjugates was analyzed
287 by ELISA to assess the IgE binding capacity. Figure 3A shows a lower IgE binding
288 capacity for OVA after conjugation with QUE. ELISA cannot predict the ability of
289 allergens to trigger degranulation of effector cells²⁴. The release of histamine, IL-6
290 and other cytokines is a characteristic and critical function of basophils²⁶. Therefore,
291 we used human basophilic KU812 cells to test the ability of samples to elicit cell
292 degranulation. As compared with native protein, the conjugates showed lower levels
293 of histamine (Figure 3B) and IL-6 (Figure 3C) with conjugation, which suggests that
294 QUE conjugation reduced the ability of OVA to trigger cell degranulation. These
295 results agree with IgE binding capacity testing by ELISA.

296

297 **In vivo assessment of allergenicity**

298 A mouse model of orally induced OVA allergy was used to assess the *in vivo*
299 allergenicity of OVA after conjugation with QUE.

300

301 *Anaphylactic shock score*

302 Anaphylactic shock symptoms were observed in BALB/c mice after challenge
303 with native OVA (Figure 4B). However, as compared with native OVA treatment, the

304 anaphylactic shock symptoms with both radical and alkaline OVA–QUE conjugate
305 were less severe (Figure 4C), with no significant difference between the radical and
306 alkaline OVA–QUE groups.

307

308 *Assessment of IgE, IgG, IgG1, histamine and MCP-1 in mouse serum.*

309 We detected serum-specific IgE, IgG, IgG1, histamine and mMCP-1 in mouse
310 serum to evaluate the allergenic potential of the OVA after conjugation with QUE. As
311 compared with OVA alone, radical and alkaline OVA-QUE conjugate groups showed
312 reduced serum levels of IgE, IgG, IgG1, histamine and mMCP-1 (Figure 4C, 4D, 4E,
313 4F and 4G).

314

315 *Assessment of cytokines in splenic cells*

316 Levels of Th2-related cytokines (IL-13, IL-4 and IL-5) and a Th1-related
317 cytokine (IFN- γ) were detected in mouse spleen to further determine whether OVA
318 conjugation with QUE could affect cytokine production in the immune response. As
319 compared with OVA alone, radical and alkaline OVA–QUE conjugate groups showed
320 a marked reduction in IL-13, IL-4 and IL-5 cytokine production in splenic cells, with
321 a slight increase in IFN- γ level (Figure 4H, 4I, 4J and 4K).

322

323 *Histopathological assessment of duodenum*

324 Histopathological assessment of duodenum is shown in Figure 5. As compared
325 with the control group, in mice sensitized with OVA and OVA–QUE conjugates, the

326 intestines were damaged. However, unmodified OVA-treated mice showed more
327 severe allergic symptoms in duodenum than both radical and alkaline OVA–QUE
328 conjugate groups.

329

330 *FcεRI⁺ and c-kit⁺ expression on peritoneal mast cells*

331 We collected peritoneal mast cells to test c-kit⁺ and FcεRI⁺ cells by flow
332 cytometry to assess the attenuation of mast cell activation after challenge with OVA
333 and its conjugates. The proportion of c-kit⁺ and FcεRI⁺ cells was greater with OVA
334 challenge than control treatment and radical and alkaline OVA–QUE treatment
335 (Figure 6).

336 Changes in the allergenicity of food allergen by conjugation with dietary
337 polyphenols have been reported; however, research on the effect *in vivo* remains
338 unclear. In this study, we evaluated the effect of QUE conjugation with OVA on
339 sensitization and the allergic response in a BALB/c mouse model. On *in vivo*
340 assessment of allergenicity in BALB/c mice, different levels of allergic symptoms
341 were triggered by OVA and its conjugates, which suggests lower allergenicity *in vivo*
342 with OVA–QUE conjugates than the native protein.

343 After conjugation with QUE, OVA relieved anaphylactic symptoms in mice. As
344 compared with native OVA, histamine secretion with OVA–QUE treatment was
345 reduced, which was consistent with the *in vitro* study. The IgE binding capacity of an
346 allergen is directly related to its IgE binding epitopes. Conjugation with QUE alters
347 OVA structures, then affects the conformational epitopes of the protein. Furthermore,

348 in our previous studies, we found that polyphenols conjugated on the surface of the
349 protein, which might affect linear IgE epitopes¹⁷⁻¹⁸. Therefore, after conjugation with
350 QUE, conformational and linear IgE epitopes in OVA may have been affected,
351 thereby reducing the IgE binding capacity, then led to decreased release of histamine.
352 Histamine will be released from basophil degranulation and mast cells and then
353 induce an allergic reaction²⁷.

354 Our OVA–QUE conjugates induced histamine significantly less than did the
355 native protein, which may be related to the weak systemic allergic symptoms.

356 FcεRI⁺ and c-kit⁺ were expressed on the surface of sensitized mast cells. Flow
357 cytometry revealed significantly higher expression of c-kit⁺ and FcεRI⁺ in
358 OVA-challenged mice than in controls, with the expression significantly reduced in
359 the OVA–QUE conjugate groups.

360 The level of mMCP-1 is key indicator for detecting mastocyte degranulation.
361 The level of mMCP-1 was higher in OVA-challenged mice than controls. As
362 compared with OVA challenge, with OVA–QUE conjugate challenge, the level of
363 mMCP-1 was significantly reduced. The results of mMCP-1 measurement were
364 consistent in the results of FcεRI⁺ and c-kit⁺ detection, which illustrates that after
365 conjugation with QUE, mastocyte degranulation was alleviated, thereby reducing the
366 allergenicity of OVA.

367 IFN-γ secreted by Th1 cells can inhibit IgE production²⁸. However, cytokines
368 including IL-13, IL-4, and IL-5 can provoke Th2 cells to produce IgE and induce an
369 IgG isotype switch to IgG1. IgG1 and IgE can induce systemic anaphylaxis²⁹ and

370 Th2-dependent antibodies ³⁰. In this study, as compared with serum from native OVA
371 challenge, that from OVA–QUE challenge showed significantly reduced levels of IgE
372 and IgG1.

373 Moreover, conjugation with QUE downregulated the Th2-related cytokines
374 (IL-13, IL-4 and IL-5) in spleen cells but upregulated the Th1 cytokine (IFN- γ), which
375 agreed with the detection of antibodies in mice. Thus, conjugation with QUE may
376 have suppressed the OVA allergic reaction by modulating the Th1/Th2 imbalance:
377 suppressing Th2 immune response and promoting the Th1 immune response.

378 We prepared OVA–QUE conjugates by radical and alkaline methods. The
379 mechanisms of these two methods are different. In the free radical method, hydroxide
380 radicals are generated by oxidation-deduction reactions between redox pair
381 components, then the radicals attack the amino acid in protein to produce radical
382 species, which react with polyphenols, inducing a covalent bond ³¹. In the alkaline
383 method, polyphenols are oxidized to form a semiquinone, which may react with some
384 residues such as histidine, cysteine and lysine residues in the chains of the protein to
385 form a covalent bond ³¹. However, the allergenicity of the radical and alkaline OVA–
386 QUE conjugates did not significantly differ. Thus, both radical and alkaline methods
387 could be used to prepare OVA–QUE conjugates with weaker allergenicity than native
388 OVA. The weaker allergenicity of OVA–QUE conjugates may be due to QUE
389 destroying and/or masking OVA epitopes.

390 To our knowledge, the interaction of polyphenols with proteins can alter the
391 immunological properties of protein by changing the protein structure and/or masking

392 epitopes and their direct effect on allergic effector cells ⁴. In addition, their
393 endogenous antioxidant ability limits the extent of cellular injury from free radicals
394 during the allergic insult ⁴. Some polyphenols show inhibitory properties against some
395 digestive enzymes, such as pepsin, which would affect the digestibility of food
396 allergens ³². In most cases, in the preparation of non-covalent protein–polyphenol
397 complexes, the unreacted polyphenols are not removed, and the polyphenols binding
398 on the protein may be released under certain conditions. So, the free polyphenols in
399 the non-covalent protein–polyphenol complex may have an important anti-allergy
400 role.

401 QUE has been investigated for its anti-allergic effect in different disease models
402 ³³⁻³⁵. In this study, unreacted QUE was removed by dialysis. Furthermore, the protein–
403 polyphenol covalent conjugate was more stable than the non-covalent protein–
404 polyphenol complex. The QUE binding on the covalent conjugate hardly moved away
405 from the conjugate. Therefore, there was no free QUE in the test samples, which may
406 not directly affect the immune cell and biological pathways in the allergic immune
407 response by the free QUE. Whether QUE covalent binding on the protein has the
408 same anti-allergic effect as free QUE deserves further investigation.

409 In conclusion, QUE could covalently conjugate with OVA and led to a changed
410 protein structure of OVA, which might destroy and/or mask OVA epitopes. The
411 conjugates showed lower allergenicity *in vitro* and *in vivo*. Conjugation with QUE
412 reduced the ability for IgE binding and triggering cell degranulation of OVA *in vitro*,
413 and the levels of specific IgE, IgG1, IgG, plasma histamine, and mMCP-1 as well as

414 FcεRI⁺ and c-kit⁺ expression on the surface of sensitized mast cells were suppressed.
415 Furthermore, conjugation with QUE modulated the imbalance of the Th1/Th2
416 immune response, which might suppress the OVA-induced allergic reaction.
417 Therefore, conjugation OVA with QUE could reduce OVA allergenicity, which may
418 help in producing hypoallergenic food.

419

420 **Funding**

421 This study was supported in part by the Research Funding for Innovation Project
422 of Universities in Guangdong Province (2018KTSCX192), Key-Area Research and
423 Development Program of Guangdong Province (2019B020213001), Medical
424 Technological Research Funding of Guangdong Province (B2018041) and Research
425 Funding of Shenzhen (JCYJ20170818143841444 and JCYJ201803053000708).

References


- (1) Sicherer, S. H.; Sampson, H. A. Food allergy: Epidemiology, pathogenesis, diagnosis, and treatment. *J. Allergy Clin. Immun.* **2014**, *133*, 291-307.
- (2) Benhamou, A. H.; Caubet, J. C.; Eigenmann, P. A.; Nowak-Wegrzyn, A.; Marcos, C. P.; Reche, M.; Urisu, A. State of the art and new horizons in the diagnosis and management of egg allergy. *Allergy* **2010**, *65*, 283-289.
- (3) Abeyrathne, E. D. N. S.; Lee, H. Y.; Ahn, D. U. Egg white proteins and their potential use in food processing or as nutraceutical and pharmaceutical agents--a review. *Poultry Sci.* **2013**, *92*, 3292-3299.
- (4) Singh, A.; Holvoet, S.; Mercenier, A. Dietary polyphenols in the prevention and treatment of allergic diseases. *Clinical & Experimental Allergy* **2011**, *41*, 1346-1359.
- (5) Liu, F.; Ma, C.; McClements, D. J.; Gao, Y. A comparative study of covalent and non-covalent interactions between zein and polyphenols in ethanol-water solution. *Food Hydrocolloid.* **2017**, *63*, 625-634.
- (6) Ozdal, T.; Capanoglu, E.; Altay, F. A review on protein - phenolic interactions and associated changes. *Food Res. Int.* **2013**, *51*, 954-970.
- (7) Pérot, M.; Lupi, R.; Guyot, S.; Delayre-Orthez, C.; Gadonna-Widehem, P.; Thébaudin, J.; Bodinier, M.; Larré, C. Polyphenol interactions mitigate the immunogenicity and allergenicity of gliadins. *J. Agr. Food Chem.* **2017**, *65*, 6442-6451.
- (8) Chung, S.; Champagne, E. T. Reducing the allergenic capacity of peanut extracts and liquid peanut butter by phenolic compounds. *Food Chem.* **2009**, *115*, 1345-1349.
- (9) Gruber, P.; Vieths, S.; Wangorsch, A.; Nerkamp, J. Maillard Reaction and Enzymatic Browning Affect the Allergenicity of Pru av 1, the Major Allergen from Cherry (*Prunus avium*). *Journal of Agriculture and Food Chemistry* **2004**, *12*, 4002-4007.
- (10) Bansode, R. R.; Plundrich, N. J.; Randolph, P. D.; Lila, M. A.; Williams, L. L. Peanut flour aggregation with polyphenolic extracts derived from peanut skin inhibits IgE binding capacity and attenuates RBL-2H3 cells degranulation via MAPK signaling pathway. *Food Chem.* **2018**, *263*, 307-314.
- (11) Plundrich, N. J.; White, B. L.; Dean, L. L.; Davis, J. P.; Foegeding, E. A.; Lila, M. A. Stability and immunogenicity of hypoallergenic peanut protein-polyphenol complexes during in vitro pepsin digestion. *Food Funct.* **2015**, *6*, 2145-2154.
- (12) Plundrich, N. J.; Bansode, R. R.; Foegeding, E. A.; Williams, L. L.; Lila, M. A. Protein-bound Vaccinium fruit polyphenols decrease IgE binding to peanut allergens and RBL-2H3 mast cell degranulation in vitro. *Food Funct.* **2017**, *8*, 1611-1621.
- (13) Bansode, R. R.; Randolph, P. D.; Plundrich, N. J.; Lila, M. A.; Williams, L. L. Peanut protein-polyphenol aggregate complexation suppresses allergic sensitization to peanut by reducing peanut-specific IgE in C3H/HeJ mice. *Food Chem.* **2019**, *299*, 125025.
- (14) Wu, X.; Zhong, X.; Liu, M.; Xia, L.; Feng, K.; Wu, H.; Liu, Z. Reduced allergenicity of β -lactoglobulin in vitro by tea catechins binding. *Food Agr. Immunol.* **2013**, *24*, 305-313.
- (15) Ognjenović, J.; Stojadinović, M.; Milčić, M.; Apostolović, D.; Vesić, J.; Stambolić, I.; Atanasković-Marković, M.; Simonović, M.; Velickovic, T. C. Interactions of epigallo-catechin 3-gallate and ovalbumin, the major allergen of egg white. *Food Chem.* **2014**, *164*, 36-43.

- (16) Ozdal, T.; Capanoglu, E.; Altay, F. A review on protein – phenolic interactions and associated changes. *Food Res. Int.* **2013**, *51*, 954-970.
- (17) Lu, Y.; Li, S.; Xu, H.; Zhang, T.; Lin, X.; Wu, X. Effect of Covalent Interaction with Chlorogenic Acid on the Allergenic Capacity of Ovalbumin. *J. Agr. Food Chem.* **2018**, *66*, 9794-9800.
- (18) He, W.; Xu, H.; Lu, Y.; Zhang, T.; Li, S.; Lin, X.; Xu, B.; Wu, X. Function, digestibility and allergenicity assessment of ovalbumin – EGCG conjugates. *J. Funct. Foods* **2019**, *61*, 103490.
- (19) Wu, X.; Lu, Y.; Xu, H.; Lin, D.; He, Z.; Wu, H.; Liu, L.; Wang, Z. Reducing the allergenic capacity of β -lactoglobulin by covalent conjugation with dietary polyphenols. *Food Chem.* **2018**, *256*, 427-434.
- (20) Xu, H.; Zhang, T.; Lu, Y.; Lin, X.; Hu, X.; Liu, L.; He, Z.; Wu, X. Effect of chlorogenic acid covalent conjugation on the allergenicity, digestibility and functional properties of whey protein. *Food Chem.* **2019**, *298*, 125024.
- (21) Rawel, H. M.; Rohn, S.; Kruse, H. P.; Kroll, J. Structural changes induced in bovine serum albumin by covalent attachment of chlorogenic acid. **2002**, 443-455.
- (22) He, W.; Xu, H.; Lu, Y.; Zhang, T.; Li, S.; Lin, X.; Xu, B.; Wu, X. Function, digestibility and allergenicity assessment of ovalbumin – EGCG conjugates. *J. Funct. Foods* **2019**, *61*, 103490.
- (23) Wu, X.; Liu, M.; Xia, L.; Wu, H.; Liu, Z.; Xu, X. Conjugation of functional oligosaccharides reduced in vitro allergenicity of β -lactoglobulin. *Food Agr. Immunol.* **2013**, *24*, 379-391.
- (24) Zhang, Y.; Wu, Z.; Li, K.; Li, X.; Yang, A.; Tong, P.; Chen, H. Allergenicity assessment on thermally processed peanut influenced by extraction and assessment methods. *Food Chem.* **2019**, *281*, 130-139.
- (25) Feng, J.; Cai, H.; Wang, H.; Li, C.; Liu, S. Improved oxidative stability of fish oil emulsion by grafted ovalbumin-catechin conjugates. *Food Chem.* **2018**, *241*, 60-69.
- (26) MacGlashan, D. W. Basophil activation testing. *J. Allergy Clin. Immun.* **2013**, *132*, 777-787.
- (27) Manuyakorn, W.; Tanpowpong, P. Cow milk protein allergy and other common food allergies and intolerances. *Paediatr Int Child Health* **2019**, *39*, 32-40.
- (28) Burton, O. T.; Medina, T. J.; Stranks, A. J.; Miller, S.; Koleoglou, K. J.; Weinberg, E. O.; Oettgen, H. C. IgE promotes type 2 innate lymphoid cells in murine food allergy. *Clin. Exp. Allergy* **2018**, *48*, 288-296.
- (29) K, S.; R, T.; E, I.; K, T.; H, Y.; T, S.; S, H.; S, H.; S, K. Lactobacillus casei strain Shirota suppresses serum immunoglobulin E and immunoglobulin G1 responses and systemic anaphylaxis in a food allergy model. *Clinical & Experimental Allergy* **2002**, *32*, 563-570.
- (30) Shi, C.; Pan, T.; Cao, M.; Liu, Q.; Zhang, L.; Liu, G. Suppression of Th2 immune responses by the sulfated polysaccharide from *Porphyra haitanensis* in tropomyosin-sensitized mice. *Int. Immunopharmacol.* **2015**, *24*, 211-218.
- (31) Rohn, S. Possibilities and limitations in the analysis of covalent interactions between phenolic compounds and proteins. *Food Res. Int.* **2014**, *65*, 13-19.
- (32) Podsedek, A.; Majewska, I.; Redzynia, M.; Sosnowska, D.; Koziolkiewicz, M. In vitro inhibitory effect on digestive enzymes and antioxidant potential of commonly consumed fruits. *J. Agr. Food Chem.* **2014**, *62*, 4610-4617.
- (33) Escribano-Ferrer, E.; Queral Regué, J.; Garcia-Sala, X.; Boix Montañés, A.; Lamuela-Raventos, R. M. In vivo anti-inflammatory and antiallergic activity of pure naringenin, naringenin chalcone, and quercetin in mice. *J. Nat. Prod.* **2019**, *82*, 177-182.
- (34) Rogerio, A. P.; Kanashiro, A.; Fontanari, C.; Da Silva, E. V. G.; Lucisano-Valim, Y. M.; Soares,

- E. G.; Faccioli, L. H. Anti-inflammatory activity of quercetin and isoquercitrin in experimental murine allergic asthma. *Inflamm. Res.* **2007**, *56*, 402-408.
- (35) Wang, B.; Hui, Y.; Liu, L.; Zhao, A.; Chiou, Y.; Zhang, F.; Pan, M. Optimized extraction of phenolics from Jujube peel and their anti-inflammatory effects in LPS-stimulated murine macrophages. *J. Agr. Food Chem.* **2019**, *67*, 1666-1673.

Figure Legends

Figure 1. SDS-PAGE analysis of OVA and OVA–QUE conjugates.



1: Marker, 2: Native OVA, 3: Radical OVA–QUE conjugate, 4: Alkaline OVA–QUE conjugate

Figure 2. Fluorescence (A), CD (B) and DSC (C) spectra for OVA and OVA–QUE conjugates.





Figure 3. IgE binding ability detected by ELISA (A), basophil histamine release with KU812 cell degranulation (B) and IL-4 release with KU812 cell degranulation (C) with OVA or radical or alkaline OVA–QUE conjugates.






Figure 4. Oral immunization of BALB/c mice with OVA or radical or alkaline OVA-QUE conjugates (A). Hypersensitivity symptoms (B) scored on a scale from 0 (no symptoms) to 5 (death) as described in Table 1. Levels of IgG (C), IgG₁ (D), IgE (E), plasma histamine (F) and mMCP-1 (G) in serum from mice. Levels of cytokines IL-13 (H), IL-4 (I), IL-5 (J) and γ -IFN (K) in mouse spleen. Results are expressed as mean \pm SD. ***p < 0.001, **P < 0.01, *P < 0.05 compared with OVA group.

Figure 5. Effects of control (A), OVA (B), radical OVA–QUE (B) and alkaline OVA–QUE (D) treatment on morphological structure of duodenum in mice.





Figure 6. FcεRI and c-kit expression on peritoneal mast cells with control (A), OVA (B), radical OVA–QUE (B) and OVA–QUE (D) treatment. The proportion of FcεRI and c-kit cells was quantified (E). ***p < 0.001, **P < 0.01, *P < 0.05 significant difference as compared with the OVA group.



Tables


Table 1. Anaphylactic symptom scoring

Score	Symptoms
0	No symptoms
1	Scratching nose and mouth
2	Swelling around the eyes and mouth; pillar erection; reduced activity; higher breathing rate
3	Shortness of breath; blue rash around the mouth and tail; higher breaching rate
4	No activity after stimulation, shivering and muscle contractions
5	Death by shock

Table 2. Characterization of OVA and OVA-QUE conjugates.

Protein/sample	Native OVA	Radical OVA-QUE	Alkaline OVA-QUE
Polyphenols bound (mg/g)	—	38.61±2.10 ^{***}	21.55±1.91 ^{***}
Free amino group (nmol/mg)	1.17±0.007	0.64±0.017 ^{***}	0.92±0.003 ^{***}
Thiol group (nmol/mg)	3.08±0.104	2.76±0.061 [*]	1.56±0.070 ^{**}
DPPH scavenging activity (μ mol Trolox/g sample)	1.53±0.1996	5.27±0.085 ^{***}	4.88±0.028 ^{***}
ABTS ⁺ scavenging activity (μ mol Trolox/g sample)	3.24±0.146	6.44±0.600 ^{**}	6.84±0.214 ^{***}

^{***}p < 0.001, ^{**}P < 0.01, ^{*}P < 0.05 significant difference as compared with the native OVA.



119x45mm (300 x 300 DPI)